No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Leap Announces Appointment of Jason Michaels as New CEO and Board Member
LEAP Awarded "Overall Practice Management Solution of the Year" Again by LegalTech Breakthrough
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
Buy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial Outlook